The Democratic Republic of Congo is now managing the fastest-spreading Ebola outbreak in recorded history, with 60 health zones across the country now affected. By Friday, the Ministry of Health had confirmed 5,794 cases and 2,786 deaths — a fatality rate of 48 percent overall, and significantly higher in the hardest-hit areas. The outbreak, which began in mid-May, has spread to two new zones in North Kivu province — Biena and Manguredjipa — where the fatality rate approaches 69 percent. The strain driving the outbreak is Bundibugyo, a rarer Ebola variant for which there is no approved vaccine or treatment. UN Secretary-General António Guterres warned Thursday that the virus is “growing faster and wider than the response to contain it.” Médecins Sans Frontières opened a new treatment centre in Beni on Friday, bringing its DRC staff count to 1,400.
The received wisdom
The dominant narrative from international health institutions is broadly accurate: this is a genuine crisis that demands urgent global solidarity, and the obstacles to containment are real. Al Jazeera’s reporting identifies the main structural barriers — armed conflict in affected provinces, population displacement, attacks on healthcare workers, inadequate infrastructure, and a mobile working population. The Bundibugyo strain’s lack of an approved vaccine is a genuine scientific constraint, not a policy failure. And the comparison to the 2014–2016 West Africa outbreak, which killed more than 11,000 people before it was contained, is appropriately alarming: the current outbreak is tracking to surpass that death toll. Pope Leo’s call for global action and Guterres’s warning are the right instincts, even if the institutions behind them have historically moved at bureaucratic rather than epidemic speed.
A different read
Here is what the global health consensus tends not to say clearly: the DRC has had nine previous Ebola outbreaks. This is not a novel threat arriving without warning. The country has been fighting Ebola, in one form or another, for half a century — the virus was first identified near the Congo River in 1976. Each outbreak has produced its own after-action reports, its own lessons-learned documents, its own promises of strengthened health systems. And yet here we are, with the fastest-spreading outbreak ever, in a country where the international response is, by the UN’s own admission, falling behind the curve.
The structural explanation is also the most honest one: eastern DRC is, by any measure, one of the most difficult operating environments on earth. The M23 armed group and dozens of other militias have made sustained public health work in North Kivu nearly impossible. Attacks on healthcare workers are not incidental; they are deliberate. The DRC’s ongoing armed conflict — and the recent, fragile roadmap for peace talks between the government and M23 — forms the backdrop against which the Ebola response is being conducted. The peace roadmap may or may not hold. The virus does not care either way.
But there is a harder question lurking behind the structural explanation: why has the world’s largest humanitarian organisation, the IFRC, deployed 1,400 MSF staff and 400 treatment beds in a country where the outbreak already spans 60 zones? That is a ratio that would strain any health system’s surge capacity. The answer, uncomfortable as it is, involves the differential value international institutions place on African lives. The COVID-19 pandemic generated trillions of dollars in global emergency spending, most of it protecting citizens of wealthy countries. The DRC Ebola outbreak — which has now killed more than 2,786 people — has generated a new MSF treatment centre.
The Bundibugyo strain’s lack of approved therapeutics is significant and deserves elaboration. The strain that caused the catastrophic 2014–2016 West Africa outbreak was Zaire Ebola, against which the rVSV-ZEBOV vaccine (brand name Ervebo) was subsequently developed and approved. Bundibugyo is a different clade. The research pipeline for Bundibugyo therapeutics exists — there are experimental monoclonal antibodies under investigation — but development has been slow, in part because the commercial market for treatments targeting diseases of the global poor is thin. This is a familiar problem: the economics of pharmaceutical development systematically underinvest in pathogens that primarily kill people who cannot pay Western drug prices. The market failure is not controversial; it is well-documented. What is less often stated is that the global architecture designed to correct this market failure — CEPI, Gavi, the Access to COVID-19 Tools Accelerator — has produced uneven results, and the Bundibugyo pipeline is an example of where it has not performed.
The historical parallel that comes to mind is the 2018–2020 DRC Ebola outbreak in North Kivu, which was the second-deadliest in history at the time. That outbreak was ultimately controlled through an aggressive ring-vaccination strategy using the Zaire-strain vaccine — which worked, but also illustrated how much of the response depended on tools developed after, and partly because of, the 2014 West Africa catastrophe. There is no equivalent tool for Bundibugyo yet. The lesson of 2018 is that vaccination technology, once developed, can change the trajectory of an outbreak dramatically. The absence of that tool in 2026 reflects a decade of underinvestment in the specific pathogen now killing people.
What to watch
Watch the WHO’s emergency committee process: if the outbreak continues its current trajectory, there will be mounting pressure to declare a Public Health Emergency of International Concern for the second time since the DRC Ebola crisis began in May. Watch whether the fragile M23 ceasefire holds, because sustained access to North Kivu is the single biggest variable in the response’s capacity to function. Watch the Bundibugyo therapeutic pipeline: any emergency use authorisation of an experimental monoclonal antibody would change the calculus significantly. And watch the international funding pledges versus actual disbursements — in past DRC health emergencies, the gap between the two has been substantial.
— J